You are here: Industry Insights > Pfizer

News List

Achievements of 5 Transnational Pharmaceutical Enterprises in China! en-CPhI.cn
August 28, 2017
Greeting Key Nodes in the Transition in China, High-speed Growth being a Normal
Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England? fiercepharma
August 25, 2017
The Swiss drugmaker’s breast cancer drug won a European green light for use in tandem with any aromatase inhibitor.
Pfizer wins Indian patent to Prevnar 13, draws cries of ‘monopoly’ from MSF fiercepharma
August 25, 2017
MSF said a patent Pfizer just got for Prevnar in India is "just a way to guarantee an extended market monopoly."
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status fiercepharma
August 24, 2017
Pfizer has already spent $2.1 million on a national TV ad for its next-gen eczema med, PDE-4 blocker Eucrisa.
Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ worldpharmanews
August 24, 2017
The Alliance Foundation Trials, LLC， in conjunction with Pfizer and six international cancer research groups, have announced the launch of PATINA - a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 inhibitor palbociclib
Pfizer lashes out at ‘frustrating’ NICE decision on ALL drug Besponsa fiercepharma
August 22, 2017
Pfizer criticized the National Institute of Health and Care Excellence for its decision that its new leukemia drug Besponsa was not cost effective.
OpenEye announces Pfizer to adopt Orion Cloud platform pharmaasia
August 22, 2017
Orion will equip chemists with all of OpenEye's software, extensive tools for data visualisation and communication.
Pfizer bags USFDA approval for Besponsa biospectrumasia
August 22, 2017
The regulatory agency approved the Besponsa, drug fro the treatment of leukemia, under Priority Review and Breakthrough Therapy status
Pfizer’s Besponsa gets FDA approval for treatment of B-cell precursor ALL pharmaceutical-technology
August 22, 2017
The US Food and Drug Administration has given approval for Pfizer’s Besponsa (inotuzumab ozogamicin) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
US regulators wave through Pfizer’s leukaemia drug pharmatimes
August 21, 2017
The US Food and Drug Administration has approved Pfizer’s Besponsa, the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page